Rizonib 250mg (Crizotinib Capsule) 250mg

Rizonib 250mg capsules contain crizotinib, a kinase inhibitor used for certain types of cancer. This oral medication is prescribed for targeted therapy in specific conditions. Store at room temperature away from moisture. Not for self-use without medical supervision.

Strength

250mg

Pack Size

30s

Storage

Ambient

Manufacturer / TM Owner

Azista Bhutan Healthcare Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Rizonib 250mg is primarily used to treat non-small cell lung cancer and anaplastic large cell lymphoma. It works by blocking abnormal signals that cause cancer cells to grow. This medication is prescribed when cancer cells have specific genetic changes. Patients may ask what is Rizonib 250mg used for to understand its role in treatment plans.

Side Effects

Rizonib 250mg capsules may cause mild to moderate effects such as nausea, vomiting, or fatigue. Some users report dizziness or vision changes during treatment. These effects vary by individual and should be monitored by a healthcare provider. Keeping a symptom diary can help track changes.

Precautions & Warnings

Keep Rizonib 250mg capsules in their original packaging at room temperature. Avoid exposure to heat or moisture to maintain potency. Do not crush, chew, or open capsules unless directed. Always follow storage instructions provided with the medication.

Avoid Interactions

Rizonib 250mg may interact with other medications, including strong CYP3A inhibitors or inducers. Avoid grapefruit products while taking this drug, as they can affect how it works. Discuss all current medications with your doctor before starting treatment. Alcohol use may increase certain side effects.

Frequently Asked Questions

Rizonib 250mg is used to treat certain types of cancer, including non-small cell lung cancer, when specific genetic changes are present.

Store Rizonib 250mg capsules at room temperature in a dry place away from direct sunlight.

Rizonib 250mg can be taken with or without food, but consistency in timing is recommended.

Common side effects may include nausea, vomiting, fatigue, or vision changes. Report persistent effects to your doctor.

Rizonib 250mg is a targeted therapy, not a traditional chemotherapy, as it works on specific cancer pathways.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.